Latest News and Press Releases

-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function Led by world-renowned research group, utilizing an...

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., May 19, 2021 (GLOBE NEWSWIRE) --...

-- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis -- CHESTERBROOK, Pa.,...

-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) --...

-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...

-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET -- CHESTERBROOK, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused...

-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis -- CHESTERBROOK, Pa., Jan. 28, 2021 (GLOBE...

-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa.,...

-- OLINVYK commercial supply on track and available in November Company funded through Q4 2022, including OLINVYK commercialization -- Company to host conference call at 8:30 a.m. ET on Monday,...